- Home
- CRT vs CVM Comparison
CRT vs CVM Comparison
Compare CRT & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | CVM |
|---|---|---|
| Founded | 1991 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 43.3M |
| IPO Year | 1992 | 1987 |
Fundamental Metrics
Financial Performance| Metric | CRT | CVM |
|---|---|---|
| Price | $8.45 | $5.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.2K | ★ 81.7K |
| Earning Date | 03-12-2026 | 02-13-2026 |
| Dividend Yield | ★ 8.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $1.98 |
| 52 Week High | $13.31 | $20.41 |
Technical Indicators
Market Signals| Indicator | CRT | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 53.14 | 40.66 |
| Support Level | $8.29 | $4.90 |
| Resistance Level | $8.85 | $6.75 |
| Average True Range (ATR) | 0.29 | 0.63 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 51.43 | 12.92 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.